GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057
Phase 1
Completed
- Conditions
- Respiratory Disorders
- Interventions
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 53
- Registration Number
- NCT01587807
- Locations
- 🇬🇧
GSK Investigational Site, Harrow, United Kingdom
The Effects of Potassium Nitrate in Reducing Dentinal Hypersensitivity
Phase 1
Completed
- Conditions
- Dental PainDentinal Hypersensitivity
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2015-04-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT01587950
- Locations
- 🇺🇸
University Park Research Center (UPRC), Fort Wayne, Indiana, United States
IMI PROTECT(WP2): Antidepressants & Fractures
Completed
- Conditions
- Depression, Postpartum
- Interventions
- Drug: Tricyclic AD (TCAs) and selective serotonin re-uptake inhibitors (SSRIs) antidepressants
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2015-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01587729
WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics
Completed
- Conditions
- Infections, Bacterial
- Interventions
- Drug: Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2014-12-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01587768
Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy
Completed
- Conditions
- Epilepsy
- Interventions
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6498
- Registration Number
- NCT01587339
Use of Beta-blockers and Risk of New Onset Diabetes
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12336
- Registration Number
- NCT01587638
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2017-11-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 72
- Registration Number
- NCT01587898
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2015-07-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 41
- Registration Number
- NCT01584843
- Locations
- 🇯🇵
GSK Investigational Site, Yamaguchi, Japan
Rechallenge, Potential Drug Induced Liver Injury (Kaiser)
Completed
- Conditions
- Drug-induced Liver Injury
- Interventions
- Drug: Prescription drugs with known hepatotoxicity
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01584765
An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed
- First Posted Date
- 2012-04-23
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT01583036
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath